Mitogen-activated protein kinases in gliomas and correlation with patients' prognosis
Article first published online: 20 SEP 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Acta Neurologica Scandinavica
Volume 129, Issue 4, pages 226–233, April 2014
How to Cite
Mitogen-activated protein kinases in gliomas and correlation with patients' prognosis. Acta Neurol Scand 2014: 129: 226–233. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd., , , , , , .
- Issue published online: 8 MAR 2014
- Article first published online: 20 SEP 2013
- Manuscript Accepted: 28 JUN 2013
- mitogen-activated protein kinases;
We examined the activation of the mitogen-activated protein kinases (MAPKs) signaling pathway in a cohort of brain gliomas, by taking advantage of a series of phosphorylation state-specific antibodies against phospho-p44/42(ERK1/2), phospho-p38, and phospho-JNK. Potential correlations between expression profiles of phospho-p44/42(ERK1/2), phospho-p38, and phospho-JNK and tumor grade, age, gender, overall survival, and Ki-67 status were also explored.
Immunohistochemistry was performed in formalin-fixed, paraffin-embedded tissues of 87 serial brain biopsies sequentially obtained for diagnostic purposes in a period of 9 years (2000–2008) from an equal number of patients with low- and high-grade gliomas.
Higher expression of all proteins in high-grade gliomas was documented. The univariate analysis revealed that high phospho-p44/42(ERK1/2) and high phospho-JNK expressions were strongly associated with decreased overall survival. However, the multivariate Cox regression failed to consider those markers as independent prognostic factors.
Activation of components of MAPK signaling pathway is associated with overall survival of patients with gliomas, thereby suggesting that the MAPK intermediates seem to play a critical role in the biologic behavior of gliomas. Further studies are needed to clarify whether these factors merit to be considered as potential therapeutic targets in future clinical trials.